GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Organogenesis Holdings
Organogenesis is a company specializing in regenerative medicine, specifically wound healing products. Its stock price reflects demand for its cutting-edge solutions for treating diabetic ulcers and other chronic wounds.
Share prices of companies in the market segment - Treatment
Organogenesis Holdings is a regenerative medicine company developing and manufacturing solutions for wound healing and surgery. We classify it in the Treatment segment because its products are directly applicable in clinical practice. The chart below shows the overall performance of this cutting-edge and important area of healthcare.
Broad Market Index - GURU.Markets
Organogenesis Holdings is a regenerative medicine company that develops and markets wound healing and sports medicine products. Its important role in healthcare earns it a spot in the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
ORGO - Daily change in the company's share price Organogenesis Holdings
Shares of Organogenesis, a regenerative medicine specialist, reflect the volatility of the healthcare sector. change_co measures the sensitivity to reimbursement rates and demand for its wound care products. This metric is important for analyzing growing medtech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Treatment
Organogenesis Holdings Inc. is a regenerative medicine company. This chart highlights the sector's high volatility. Comparing it to ORGO, which focuses on wound healing, helps us assess it as an innovative player.
Daily change in the price of a broad market stock, index - GURU.Markets
Organogenesis is a leader in regenerative medicine, producing wound healing products. The medical technology market is growing rapidly. The chart below shows the volatility in this sector, helping to assess how Organogenesis shares are responding to innovation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Organogenesis Holdings
Organogenesis is a leader in regenerative medicine. Its year-over-year performance reflects its rapid growth and the adoption of its technologies in clinical practice. The chart below tells the story of this leading medical technology company.
Annual dynamics of market capitalization of the market segment - Treatment
Organogenesis Holdings Inc. is a leading regenerative medicine company specializing in wound healing products. This chart shows how its innovative products, growth in this important healthcare segment, and reliance on reimbursement systems influence its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Organogenesis, specializing in regenerative medicine for wound healing, is a growth story in healthcare. Its stock price is driven not by the economy, but by demand for its innovative products and the insurance system. The chart reflects the potential of this breakthrough technology in the vast chronic wound treatment market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Organogenesis Holdings
The value of Organogenesis, a regenerative medicine company, depends on the adoption of its products. The monthly fluctuations in the chart reflect the sales volumes of its wound healing products, which are sensitive to insurance reimbursement rates and competition in the market.
Monthly dynamics of market capitalization of the market segment - Treatment
This chart shows the dynamics of the healthcare sector, particularly regenerative medicine. For Organogenesis, a leader in this field, this is the backdrop. Its movements reflect demand for its wound healing products, driven by an aging population and rising diabetes rates.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Organogenesis is a leading regenerative medicine company producing bioengineered "living" tissues for wound healing. Demand for its products is growing. A full-market chart allows you to assess how strong its own growth trend, driven by the implementation of its technology, allows Organogenesis shares to move independently of overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Organogenesis Holdings
Organogenesis, a company specializing in regenerative medicine and wound treatment, is responding to healthcare news. Weekly stock performance reflects insurance company coverage decisions and data on the clinical efficacy of its products.
Weekly dynamics of market capitalization of the market segment - Treatment
Organogenesis, like other companies in the regenerative medicine sector, is dependent on overall healthcare trends. Insurance company decisions on covering expensive procedures and hospital budgets are common factors. The graph will show whether ORGO is ahead of the industry, confirming demand for its wound treatment products.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a healthcare company, Organogenesis can demonstrate defensive qualities by moving out of sync with the broader market. Demand for its regenerative medicine products is less dependent on economic cycles. The chart will help assess whether ORGO truly is a safe haven during periods of general market turbulence.
Market capitalization of the company, segment and market as a whole
ORGO - Market capitalization of the company Organogenesis Holdings
Organogenesis's chart tells the story of regenerative medicine and wound healing. The company produces bioengineered "living" tissues to treat chronic wounds, such as diabetic ulcers. Its market capitalization reflects how investors assess the demand for these advanced treatments and their market penetration.
ORGO - Share of the company's market capitalization Organogenesis Holdings within the market segment - Treatment
Organogenesis Holdings is a leader in regenerative medicine, developing and marketing products for wound healing and sports medicine. Its market share reflects its dominance in this niche. The chart below shows how investors view the growth of its products and the competitive landscape.
Market capitalization of the market segment - Treatment
Organogenesis Holdings is a leader in regenerative medicine, producing living bioengineered tissues for wound healing. The chart below shows the market capitalization of this innovative sector. Its valuation reflects the potential of technologies that help the body regenerate.
Market capitalization of all companies included in a broad market index - GURU.Markets
Organogenesis Holdings is a regenerative medicine company that develops and markets products for wound healing and sports medicine. Its market capitalization reflects the need for advanced treatments for complex wounds, such as those associated with diabetes. Its stake in the healthcare sector reflects the weight of technologies that help the body repair damaged tissue.
Book value capitalization of the company, segment and market as a whole
ORGO - Book value capitalization of the company Organogenesis Holdings
Organogenesis is a regenerative medicine company. It includes state-of-the-art facilities where "bioactive wound dressings" are grown from living cells to treat diabetic ulcers and other complex wounds. The chart below shows how the company has invested in its unique biotech manufacturing assets.
ORGO - Share of the company's book capitalization Organogenesis Holdings within the market segment - Treatment
Organogenesis manufactures regenerative medicine products at its own manufacturing facilities. These high-tech, sterile facilities are its main tangible asset. The S_BCap_Seg graph shows the company's share of the bioengineered tissue infrastructure.
Market segment balance sheet capitalization - Treatment
The field of regenerative medicine, as the chart shows, requires unique assets. Organogenesis is a prominent example. Its business is capital-intensive, as it requires ultra-clean production facilities to create "living" bioengineered tissues.
Book value of all companies included in the broad market index - GURU.Markets
Organogenesis is a pioneer in regenerative medicine, creating living bioengineered tissues for wound healing. The company's assets include unique production labs where these "spare parts" for the body are grown. The chart below illustrates the material weight behind this cutting-edge medical technology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Organogenesis Holdings
Organogenesis balances unique "factories" for growing living tissue for wound healing. The market values the company at a huge premium, seeing it as a leader in the revolutionary field of regenerative medicine. The chart shows the price investors are paying for this technology for "repairing" the human body.
Market to book capitalization ratio in a market segment - Treatment
Organogenesis Holdings is a regenerative medicine company producing bioengineered "living" tissues for wound healing. Its value lies in its unique products and technologies. This chart shows the premium the market pays for its innovations in chronic wound treatment over the value of its production assets.
Market to book capitalization ratio for the market as a whole
Organogenesis Holdings is a regenerative medicine company that develops and markets products for wound healing and sports medicine. Its value is determined by its portfolio of approved products, patents, and commercial infrastructure. The chart shows how the market values its leadership in niche but important areas of modern medicine.
Debts of the company, segment and market as a whole
ORGO - Company debts Organogenesis Holdings
Organogenesis, a regenerative medicine company, is using debt financing to scale production and commercialize its wound healing products. This chart shows how the company is investing in expanding its sales force and manufacturing capacity to meet growing demand from hospitals and clinics.
Market segment debts - Treatment
Organogenesis Holdings specializes in regenerative medicine, developing and manufacturing bioengineered products for wound healing and sports medicine. The company's rapid growth requires investment in production expansion and R&D. This chart shows how the company's leverage supports its expansion into the advanced medical technology market and aligns with industry standards.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Organogenesis Holdings
Organogenesis, unlike many biotechs, already has commercial products in the field of regenerative medicine. For them, debt is not just a means of survival, but a tool for expanding production and sales. This chart shows how a healthcare operating company uses debt capital to scale its business.
Market segment debt to market segment book capitalization - Treatment
Organogenesis, a regenerative medicine company developing and marketing products for wound healing and sports medicine, compares its debt to the overall market capitalization of the sector. It shows how the company finances its commercial activities and research to expand the applications of its innovative bioengineered products.
Debt to book value of all companies in the market
Organogenesis Holdings specializes in regenerative medicine, creating wound healing products. Growth in this innovative medical field requires investment in R&D and marketing. This chart illustrates the overall debt situation in the economy, which helps assess how the company is financing its expansion and the sustainability of its financial policies.
P/E of the company, segment and market as a whole
P/E - Organogenesis Holdings
This chart for Organogenesis Holdings shows the valuation of a leading regenerative medicine company producing bioengineered wound healing products. Profitability depends on the widespread adoption of its technologies in hospitals. The high valuation reflects investor expectations for growing demand for advanced chronic wound treatments.
P/E of the market segment - Treatment
Organogenesis Holdings is a leading regenerative medicine company, specializing in the development and commercialization of wound healing and surgical tissue repair products. This chart illustrates the average valuation in the medical technology sector, where investors highly value innovative products that solve complex medical problems.
P/E of the market as a whole
Organogenesis Holdings develops and markets regenerative medicine products, primarily for wound healing. Demand for its products is supported by the rising incidence of chronic diseases such as diabetes. This chart reflects overall market sentiment. It helps us understand whether the company is a growth story in medicine, independent of market fluctuations, or whether it is also affected by general sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Organogenesis Holdings
The chart for Organogenesis Holdings shows how the market views the company's future revenue in the regenerative medicine field. This metric reflects analysts' expectations for growth in demand for its bioengineered wound healing products, allowing investors to understand how the current share price aligns with growth projections for the sector.
%20P%2FE%20Organogenesis%20Holdings&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Organogenesis-Holdings&v=1772513784738 "Chart of the company's future (projected) P/E Organogenesis Holdings")
Future (projected) P/E of the market segment - Treatment
Organogenesis Holdings specializes in regenerative medicine, developing bioactive wound healing products. The chart below shows average expectations for the biotech sector. ORGO's position may reflect investors' confidence in its product portfolio and its ability to achieve market leadership in advanced chronic wound treatment solutions.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Treatment&v=1772513784770 "Future (projected) P/E graph of the market segment - Treatment")
Future (projected) P/E of the market as a whole
Organogenesis Holdings specializes in regenerative medicine. Demand for its products is driven by healthcare needs and is not significantly affected by short-term economic cycles. However, overall investor sentiment, as shown in this chart, influences the valuation of the entire medical technology sector.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513784792 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Organogenesis Holdings
Organogenesis Holdings develops and manufactures regenerative medicine products for the treatment of wounds and sports injuries. This chart shows how cutting-edge biotechnology is converted into revenue. The company's growing profits mean that its innovative solutions, such as living skin equivalents, are increasingly being used in hospitals to accelerate patient healing.
Profit of companies in the market segment - Treatment
Organogenesis Holdings is a leader in regenerative medicine, creating bioengineered tissue products for wound healing. The profitability of the medical procedures and treatments sector demonstrates how the healthcare system is investing in cutting-edge technologies. For ORGO, growth on this chart signifies acceptance of its products and hospitals' willingness to pay for more effective treatments.
Overall market profit
Organogenesis Holdings, a leader in regenerative medicine, specializes in the treatment of chronic wounds. Demand for its products is driven by an aging population and rising rates of chronic diseases, making it resilient to economic cycles. However, the overall profitability of the corporate sector, reflected in the graph, impacts the budgets of hospitals and insurance companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Organogenesis Holdings
Organogenesis specializes in regenerative medicine, specifically wound healing products. This chart shows analysts' forecasts for future profits, which are based on sales volumes of its bioengineered tissues. Investors view this as an estimate of the growth of the market for advanced treatments for chronic wounds, such as diabetic ulcers.
%20profit%20of%20the%20company%20Organogenesis%20Holdings&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Organogenesis-Holdings&v=1772513784961 "Graph of future (projected) profit of the company Organogenesis Holdings")
Future (predicted) profit of companies in the market segment - Treatment
Organogenesis Holdings is a leader in regenerative medicine, creating living bioengineered products for wound healing. Demand for its technologies is growing alongside the prevalence of chronic diseases. This chart shows the revenue forecast for the medical technology sector, reflecting expectations for the introduction of innovative treatments into clinical practice.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Treatment&v=1772513785008 "Graph of future (predicted) profits of companies in a market segment - Treatment")
Future (predicted) profit of the market as a whole
Organogenesis Holdings specializes in regenerative medicine and wound healing. Demand for its products is largely driven by medical needs and is less dependent on economic cycles. However, the healthcare system as a whole is sensitive to economic conditions, and hospital budget cuts during a recession can slow the adoption of new technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513785089 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Organogenesis Holdings
Organogenesis Holdings is a leader in regenerative medicine, developing and marketing products for wound healing, surgery, and sports medicine. Its revenue is directly tied to the clinical adoption of its bioengineered tissues. This chart shows how highly the market values each dollar of sales, seeing enormous potential in replacing traditional treatments.
P/S market segment - Treatment
Organogenesis Holdings specializes in regenerative medicine, developing bioactive products for wound healing and tissue regeneration. The chart shows the average revenue estimate for the medical technology sector. It allows us to assess how much investors believe in the growth potential of its innovative products compared to traditional treatments.
P/S of the market as a whole
Organogenesis Holdings specializes in regenerative medicine, developing and marketing wound healing products. Its revenue is growing due to an aging population and the rise of diabetes. The chart provides context for assessing how much the market is willing to pay for the revenue of a company solving pressing medical problems, compared to the overall economy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Organogenesis Holdings
Organogenesis Holdings is a leader in regenerative medicine, specializing in wound healing products. This chart reflects investor expectations for the growth of the advanced medical technology market, valuing the company based on projected future sales of its innovative bioactive products for the treatment of chronic wounds.
%20P%2FS%20Organogenesis%20Holdings&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Organogenesis-Holdings&v=1772513785290 "The graph of the company's future (projected) P/S Organogenesis Holdings")
Future (projected) P/S of the market segment - Treatment
Organogenesis Holdings is a leader in regenerative medicine, developing bioactive wound dressings and skin substitutes. This chart shows the average future revenue estimates for companies in the medical technology sector. It provides insight into how investors value Organogenesis's innovative products and its growth potential in the wound treatment market.
%20P%2FS%20market%20segment%20graph%20-%20Treatment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Treatment&v=1772513785336 "Future (projected) P/S market segment graph - Treatment")
Future (projected) P/S of the market as a whole
Organogenesis Holdings is a leader in regenerative medicine. Demand for its wound healing products is driven by medical needs, not the state of the economy. This indicator is secondary to the company's overall revenue expectations. Growth drivers include an aging population, the prevalence of diabetes, and the innovativeness of its technologies.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513785396 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Organogenesis Holdings
Organogenesis is a leader in regenerative medicine, producing bioengineered tissue analogs for wound healing. The company's sales, shown in this chart, reflect the degree to which its cutting-edge products are being adopted into clinical practice. Revenue growth means that more and more hospitals and physicians are choosing their technologies to treat complex wounds.
Sales of companies in the market segment - Treatment
Organogenesis Holdings is a regenerative medicine company that develops and commercializes wound healing and tissue repair solutions. Their products are used to treat chronic wounds, such as diabetic foot ulcers. This chart shows the sector's total revenue, reflecting the growing need for advanced treatments and tissue repair.
Overall market sales
Organogenesis Holdings specializes in regenerative medicine, creating bioengineered tissues for wound healing. This chart reflects the overall economic situation, but demand for ORGO products is driven by the needs of the healthcare system. An aging population and the prevalence of chronic diseases such as diabetes create a constant need for advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Organogenesis Holdings
Organogenesis Holdings is a leader in regenerative medicine, developing bioactive wound dressings. Demand for its products is growing due to the increasing number of patients with chronic wounds, such as those associated with diabetes. This chart reflects forecasts for the adoption of advanced treatments and growth of the bioengineered tissue market.
%20sales%20of%20the%20company%20Organogenesis%20Holdings&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Organogenesis-Holdings&v=1772513785545 "Schedule of future (projected) sales of the company Organogenesis Holdings")
Future (projected) sales of companies in the market segment - Treatment
Organogenesis Holdings is a leader in regenerative medicine, creating bioengineered tissue products for wound healing and surgery. Its technologies help the body regenerate. This chart shows forecasts for the entire medical procedure sector. An aging population and the rise of chronic diseases are driving long-term demand for the company's products.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Treatment&v=1772513785580 "Schedule of future (projected) sales of companies in the market segment - Treatment")
Future (projected) sales of the market as a whole
Organogenesis Holdings specializes in regenerative medicine, offering wound healing solutions. Demand for its products is driven by healthcare costs. The overall economic situation, reflected in this chart, impacts hospital budgets and patient solvency. Economic growth ensures stable funding for medical services, supporting demand for ORGO products.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513785610 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Organogenesis Holdings
Organogenesis Holdings is a leader in regenerative medicine, creating wound healing products. Their profitability depends on the introduction of innovative and effective treatments into clinical practice. This chart shows how successfully the company translates its scientific research into profitable medical solutions that meet market demand.
Market segment marginality - Treatment
Organogenesis Holdings specializes in regenerative medicine, developing and marketing products for wound healing and sports medicine. This chart shows the average profitability in the medical technology sector. Its leadership in the bioengineered cell technology niche allows the company to maintain high growth rates and profitability above the industry average.
Market marginality as a whole
Organogenesis Holdings specializes in regenerative medicine, offering solutions for wound healing and sports medicine. The company's profitability depends on innovative products and their acceptance by the medical community. This total corporate return chart illustrates how cutting-edge medical technologies can be a profitable business.
Employees in the company, segment and market as a whole
Number of employees in the company Organogenesis Holdings
Organogenesis is a regenerative medicine company. It develops, manufactures, and markets its products in-house. Its team includes scientists, production personnel, and specialized sales representatives working with clinics. The growth in this graph directly indicates increasing demand and scaling up production.
Share of the company's employees Organogenesis Holdings within the market segment - Treatment
Organogenesis Holdings is a leader in regenerative medicine, creating living bioengineered tissues for wound healing. This complex production and scientific process requires unique specialists. This indicator reflects the share of experts in this cutting-edge medical niche the company attracts, demonstrating its dominant position and scientific authority.
Number of employees in the market segment - Treatment
Organogenesis Holdings Inc. is a leader in regenerative medicine, offering solutions for wound healing and sports medicine. The accelerated hiring, particularly in sales and marketing, shown in the chart, is directly related to the company's expanding product penetration in hospitals and clinics, as well as the launch of new developments.
Number of employees in the market as a whole
Organogenesis Holdings Inc. is a leader in regenerative medicine. Demand for its wound healing products is driven by healthcare system needs, not by overall employment. However, stable employment provides a wide range of patients with access to insurance that covers the use of such advanced treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Organogenesis Holdings (ORGO)
Organogenesis Holdings is a regenerative medicine company. It not only develops but also manufactures and sells its products. This chart reflects a hybrid model: the high value of intellectual property is combined with the need for production and sales personnel, resulting in a high but balanced per-employee ratio.
%20of%20the%20company%20Organogenesis%20Holdings%20(ORGO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Organogenesis-Holdings-ORGO&v=1772513785815 "Chart of market capitalization per employee (in thousands of dollars) of the company Organogenesis Holdings (ORGO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Treatment
Organogenesis Holdings is a leader in regenerative medicine, producing bioengineered wound healing products. The company combines cutting-edge scientific research with in-house manufacturing. This chart shows how the market values this knowledge-intensive manufacturing model per employee.
%20by%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Treatment&v=1772513785889 "Market capitalization per employee (in thousands of dollars) by market segment - Treatment")
Market capitalization per employee (in thousands of dollars) for the overall market
Organogenesis Holdings specializes in regenerative medicine, developing bioengineered tissues for wound healing. This chart shows the valuation of medical innovations. It reflects how the market values the value created by the team of scientists and specialists whose products help treat complex chronic wounds.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513785964 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Organogenesis Holdings (ORGO)
Organogenesis Holdings specializes in regenerative medicine, creating "living" tissue products for wound healing. This is a high-tech biomanufacturing company. This graph shows how profitable this complex process is. It measures the net profit generated by each employee, from the lab scientist to the production specialist. This is an indicator of efficiency at the intersection of biotech and manufacturing.
%20Chart%20Organogenesis%20Holdings%20(ORGO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Organogenesis-Holdings-ORGO&v=1772513785993 "Company Profit Per Employee (in thousands of dollars) Chart Organogenesis Holdings (ORGO)")
Profit per employee (in thousands of dollars) in the market segment - Treatment
Organogenesis (ORGO) is "regenerative medicine" (bioengineered tissues for wounds). This chart shows the benchmark for "Treatment." The average profit per employee in this sector is high. It's an "R&D business." The benchmark reflects the high margins of patented, one-of-a-kind B2B procedures (for hospitals).
%20in%20the%20market%20segment%20-%20Treatment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Treatment&v=1772513786037 "Chart of profit per employee (in thousands of dollars) in the market segment - Treatment")
Profit per employee (in thousands of dollars) for the market as a whole
Organogenesis Holdings specializes in regenerative medicine—the creation of bioengineered "living" tissues for wound healing. This is a complex biotech process that requires R&D and sterile manufacturing. This chart shows how much profit each employee generates in the innovative, yet complex and competitive, medical technology sector.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513786115 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Organogenesis Holdings (ORGO)
Organogenesis Holdings specializes in regenerative medicine. This chart shows how the company is commercializing its cutting-edge biomedical products. The increase in revenue per employee reflects increased demand from hospitals and clinics, as well as the effectiveness of its manufacturing and sales teams.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Organogenesis-Holdings-ORGO&v=1772513786176 "Sales chart per company employee Organogenesis Holdings (ORGO)")
Sales per employee in the market segment - Treatment
Organogenesis (ORGO) specializes in regenerative medicine—the production of living bioengineered products for wound healing. This is a complex biotech production facility. This graph illustrates their production and commercial efficiency. The high price point of their innovative products allows them to generate significant revenue per employee engaged in production and sales.
Sales per employee for the market as a whole
Organogenesis specializes in regenerative medicine, creating living bioengineered wound-healing products. This is a complex biotech manufacturing operation. This metric measures how efficiently the company produces and markets these high-tech medical products per employee, including R&D and manufacturing.
Short shares by company, segment and market as a whole
Shares shorted by company Organogenesis Holdings (ORGO)
Organogenesis (ORGO) is a leader in regenerative medicine. They create living bioengineered products (skin and tissue substitutes) to treat complex wounds, burns, and surgical injuries. This figure reflects skepticism. Investors may be concerned about changes to Medicare reimbursement rules, a key driver of their revenue.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Organogenesis-Holdings-ORGO&v=1772513786239 "Short Shares Chart for the Company Organogenesis Holdings (ORGO)")
Shares shorted by market segment - Treatment
Organogenesis (ORGO) is a company specializing in regenerative medicine, specifically the production of living skin substitutes for the treatment of chronic wounds (diabetic foot). This chart shows bets against the MedTech sector. The rising bets against the industry may reflect investor concerns about changes to Medicare reimbursement rules.
Shares shorted by the overall market
Organogenesis (ORGO) develops and markets regenerative medicine products, primarily for complex wound healing (diabetic foot). This chart shows the overall market anxiety. Although their products are medical, the rising market anxiety may reflect investor concerns about the reimbursement system (insurance) or pressure on hospital budgets, which are their primary clients.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Organogenesis Holdings (ORGO)
Organogenesis is a regenerative medicine company producing living skin substitutes for treating chronic wounds (such as diabetic ulcers). This chart measures how the market perceives their growth and, more importantly, the risk of reimbursement (Medicare). It shows peaks of optimism (overbought) or fear (oversold).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Organogenesis-Holdings-ORGO&v=1772513786330 "RSI 14 indicator chart for the company's stock Organogenesis Holdings (ORGO)")
RSI 14 Market Segment - Treatment
Organogenesis is a regenerative medicine company specializing in the treatment of chronic wounds (such as diabetic foot ulcers) using bioengineered living tissues. This metric reflects the overall momentum in the medical technology sector and helps determine whether the sector is being oversold due to changes in the reimbursement system.
RSI 14 for the overall market
Organogenesis (ORGO) produces tissue regeneration products (wound treatment). This chart shows that its business is "defensive." Demand for chronic wound treatment (diabetes) is not affected by euphoria or panic. During periods of market panic, investors seek safe havens in companies with non-cyclical demand.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ORGO (Organogenesis Holdings)
Organogenesis Holdings specializes in regenerative medicine, producing bioengineered "living" tissues for the treatment of chronic wounds (such as diabetic foot). This chart shows the average analyst forecast. Their targets depend on sales growth of their flagship products and a favorable reimbursement policy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ORGO-Organogenesis-Holdings&v=1772513786418 "A chart showing analyst consensus forecasts for the expected stock price. ORGO (Organogenesis Holdings)")
The difference between the consensus estimate and the actual stock price ORGO (Organogenesis Holdings)
Organogenesis is a regenerative medicine company. They produce and market bioengineered skin substitutes and other products for the treatment of chronic wounds, burns, and surgical injuries. This chart shows analysts' estimates of demand for their advanced wound treatments and insurance reimbursement issues.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ORGO-Organogenesis-Holdings&v=1772513786429 "A chart showing the difference between the consensus forecast and the actual stock price. ORGO (Organogenesis Holdings)")
Analyst consensus forecast for stock prices by market segment - Treatment
Organogenesis is a leader in regenerative medicine. The company produces "living" bioengineered patches from skin cells for the treatment of chronic wounds (like diabetic foot). This chart shows analysts' overall expectations for the treatment sector. It reflects whether experts believe the high-tech wound care market will grow.
Analysts' consensus forecast for the overall market share price
Organogenesis Holdings is a regenerative medicine company producing bioengineered living skin substitutes for the treatment of chronic wounds (such as diabetic ulcers). This chart shows the overall market sentiment. For Organogenesis, which operates in the protective healthcare sector, overall optimism is important for funding, but their demand is driven by the need to treat complex medical conditions.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Organogenesis Holdings
Organogenesis (ORGO) is a regenerative medicine company. They produce bioengineered living products (skin and tissue substitutes) for the treatment of chronic wounds (diabetic foot) and surgery. This chart evaluates their unique technology. It reflects the rate of adoption of their products in hospitals and their ability to receive reimbursement from insurance companies (Medicare) for these expensive treatments.
AKIMA Market Segment Index - Treatment
Organogenesis (ORGO) is a leader in regenerative medicine (like MiMedx); the company produces innovative bioengineered products based on living cells for the treatment of chronic wounds. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does this niche (wound treatment) model (ORGO) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Organogenesis is a leader in regenerative medicine, specializing in the treatment of chronic wounds and sports injuries. This chart, reflecting the market average, provides context. It helps assess how this "protective" business, dependent on insurance coverage and demographics, compares to overall macroeconomic fluctuations.
